Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,20564143,AUC-based accumulation factors,"Mean+/-standard deviation AUC-based accumulation factors for everolimus on Days 8 and 15 were 1.16+/-0.37 and 1.42+/-0.42, respectively.","Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),,1.16,3930,DB01590,Everolimus
,20564143,AUC-based accumulation factors,"Mean+/-standard deviation AUC-based accumulation factors for everolimus on Days 8 and 15 were 1.16+/-0.37 and 1.42+/-0.42, respectively.","Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),,1.42,3931,DB01590,Everolimus
,20564143,Day 1,Docetaxel Day 1 half-life was 9.4+/-3.4 hours.,"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),h,9.4,3932,DB01590,Everolimus
,20564143,half-life,Docetaxel Day 1 half-life was 9.4+/-3.4 hours.,"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),h,9.4,3933,DB01590,Everolimus
,23579358,AUC,"A Bayesian dose-escalation model was used to identify feasible daily or weekly everolimus doses given with paclitaxel (200 mg/m(2) q21 days) and carboplatin (AUC 6 mg/mL/min q21 days) (step 1) and paclitaxel (200 mg/m(2) q21 days), carboplatin (AUC 6 mg/mL/min q21 days), and bevacizumab (15 mg/kg q21 days) (step 2).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),[mg] / [min·ml],6,11334,DB01590,Everolimus
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,16.7,11335,DB01590,Everolimus
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,30.8,11336,DB01590,Everolimus
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,30.0,11337,DB01590,Everolimus
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,52,11753,DB01590,Everolimus
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,35,11754,DB01590,Everolimus
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,30,11755,DB01590,Everolimus
,30129060,steady-state mean,"The steady-state mean areas under the concentration-time curves of lenvatinib and everolimus were 3220 and 401 ng·h/mL, respectively.",Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30129060/),[h·ng] / [ml],3220,13995,DB01590,Everolimus
,30129060,areas under the concentration-time curves,"The steady-state mean areas under the concentration-time curves of lenvatinib and everolimus were 3220 and 401 ng·h/mL, respectively.",Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30129060/),[h·ng] / [ml],3220,13996,DB01590,Everolimus
,30129060,areas under the concentration-time curves,"The steady-state mean areas under the concentration-time curves of lenvatinib and everolimus were 3220 and 401 ng·h/mL, respectively.",Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30129060/),[h·ng] / [ml],401,13997,DB01590,Everolimus
,12616666,bioavailability,"The bioavailability of everolimus from the dispersible tablet was 10% lower relative to the conventional tablet, with a ratio (90% confidence interval) of 0.90 (0.76-1.07).","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),%,10,17074,DB01590,Everolimus
,12616666,AUC ratio,"Overall absorption, however, was not affected by food inasmuch as the fed/fasting AUC ratio was 0.99 (0.83-1.17).","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),,0.99,17075,DB01590,Everolimus
,12616666,Cmin,"The corresponding steady-state parameters were as follows: Cmin, 4.4 +/- 1.7 ng/ml; Cmax, 13.6 +/- 4.2 ng/ml; and AUC, 87 +/- 27 ng.h/ml.","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),[ng] / [ml],4.4,17076,DB01590,Everolimus
,12616666,Cmax,"The corresponding steady-state parameters were as follows: Cmin, 4.4 +/- 1.7 ng/ml; Cmax, 13.6 +/- 4.2 ng/ml; and AUC, 87 +/- 27 ng.h/ml.","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),[ng] / [ml],13.6,17077,DB01590,Everolimus
,12616666,AUC,"The corresponding steady-state parameters were as follows: Cmin, 4.4 +/- 1.7 ng/ml; Cmax, 13.6 +/- 4.2 ng/ml; and AUC, 87 +/- 27 ng.h/ml.","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),[h·ng] / [ml],87,17078,DB01590,Everolimus
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,48.0,21662,DB01590,Everolimus
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,21.2,21663,DB01590,Everolimus
,28357727,clearance,Non-compartmental and population pharmacokinetic-based simulations indicated significant increases in everolimus Cmax and AUC0-24 on day 28 and decreased clearance to 13.41 L/hr.,A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28357727/),[l] / [h],13.41,24436,DB01590,Everolimus
,16563975,C0,This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml).,Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563975/),[ng] / [ml],6.6,24661,DB01590,Everolimus
,26274696,time of the conversion,Mean time of the conversion was 61 months after transplantation.,Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),month,61,25023,DB01590,Everolimus
,26274696,trough blood concentration,"In the first 7 patients, the initial EVR dose of 3 mg BID resulted in mean EVR trough blood concentration of 14.7 ± 3.7 ng/mL at day 7.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],14.7,25024,DB01590,Everolimus
,26274696,trough blood concentration,"Four weeks after conversion, mean EVR dose was 1.7 ± 0.5 mg BID (7 patients were receiving 1 mg BID and 17 were receiving 2 mg BID) resulting in mean EVR trough blood concentration of 4.0 ± 1.4 ng/mL.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.0,25025,DB01590,Everolimus
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],13.4,25026,DB01590,Everolimus
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],22.9,25027,DB01590,Everolimus
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],232,25028,DB01590,Everolimus
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],366,25029,DB01590,Everolimus
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],78.2,25030,DB01590,Everolimus
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],102.5,25031,DB01590,Everolimus
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],3.7,25032,DB01590,Everolimus
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.1,25033,DB01590,Everolimus
,28762135,C max,"On the 10 mg once-daily schedule, C max, minimum concentration (C min), and area under the concentration-time curve from time zero to 24 h (AUC24) were 61.5 ng/mL [mean percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL (CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively.",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],61.5,26563,DB01590,Everolimus
,28762135,minimum concentration (C min),"On the 10 mg once-daily schedule, C max, minimum concentration (C min), and area under the concentration-time curve from time zero to 24 h (AUC24) were 61.5 ng/mL [mean percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL (CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively.",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],9.6,26564,DB01590,Everolimus
,28762135,area under the concentration-time curve from time zero to 24 h (AUC24),"On the 10 mg once-daily schedule, C max, minimum concentration (C min), and area under the concentration-time curve from time zero to 24 h (AUC24) were 61.5 ng/mL [mean percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL (CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively.",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[h·ng] / [ml],435,26565,DB01590,Everolimus
,28762135,C max,"Switching to the 5 mg twice-daily schedule resulted in a reduction of C max to 40.3 ng/mL (CV% 46.6) (p = 0.013), while maintaining AUC24 at 436 ng h/mL (CV% 34.8) (p = 0.952).",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],40.3,26566,DB01590,Everolimus
,28762135,AUC24,"Switching to the 5 mg twice-daily schedule resulted in a reduction of C max to 40.3 ng/mL (CV% 46.6) (p = 0.013), while maintaining AUC24 at 436 ng h/mL (CV% 34.8) (p = 0.952).",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[h·ng] / [ml],436,26567,DB01590,Everolimus
,28762135,C min,C min increased to 13.7 ng/mL (CV% 53.9) (p = 0.018).,Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],13.7,26568,DB01590,Everolimus
,28762135,C max/C min ratio,The C max/C min ratio was reduced from 6.44 (CV% 36.2) to 3.18 (CV% 35.5) (p < 0.001).,Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),,6.44,26569,DB01590,Everolimus
,28762135,C max/C min ratio,The C max/C min ratio was reduced from 6.44 (CV% 36.2) to 3.18 (CV% 35.5) (p < 0.001).,Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),,3.18,26570,DB01590,Everolimus
,11069439,"area under the blood concentration-time curve to 12 h (AUC(0,12 h))","The mean area under the blood concentration-time curve to 12 h (AUC(0,12 h)) was 4244 +/- 1311 microg l-1 h for cyclosporin before SDZ RAD treatment and 4683 +/- 1174 microg l-1 h (P = 0.106) on the day of SDZ RAD treatment (95% CI for difference -126, 1003).",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],4244,29800,DB01590,Everolimus
,11069439,"area under the blood concentration-time curve to 12 h (AUC(0,12 h))","The mean area under the blood concentration-time curve to 12 h (AUC(0,12 h)) was 4244 +/- 1311 microg l-1 h for cyclosporin before SDZ RAD treatment and 4683 +/- 1174 microg l-1 h (P = 0.106) on the day of SDZ RAD treatment (95% CI for difference -126, 1003).",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],4683,29801,DB01590,Everolimus
,11069439,"AUC(0,24 h)","The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],35.4,29802,DB01590,Everolimus
,11069439,Cmax,"The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[μg] / [l],7.9,29803,DB01590,Everolimus
,11069439,tmax,"The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),h,1.5,29804,DB01590,Everolimus
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,17,31814,DB01590,Everolimus
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,20,31815,DB01590,Everolimus
,32436621,progression free survival (PFS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,3.25,31816,DB01590,Everolimus
,32436621,overall survival (OS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,5.85,31817,DB01590,Everolimus
,34041638,Ctrough,The optimal Ctrough cutoff predicting DLT development was 17.3 ng/mL.,Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,33999,DB01590,Everolimus
≥,34041638,Ctrough,"The cumulative incidence of DLTs was significantly higher in patients with Ctrough ≥17.3 ng/mL than in other patients (sub-hazard ratio 4.87, 95 % confidence interval [CI] 1.53-15.5; P = 0.007).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,34000,DB01590,Everolimus
,34041638,PFS,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,327,34001,DB01590,Everolimus
,34041638,PFS,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,194,34002,DB01590,Everolimus
,34041638,steady-state Ctrough,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,327,34003,DB01590,Everolimus
,34041638,steady-state Ctrough,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,194,34004,DB01590,Everolimus
,34041638,Ctrough,The suggested upper threshold for the therapeutic window of everolimus Ctrough was 17.3 ng/mL.,Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,34005,DB01590,Everolimus
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,32,36262,DB01590,Everolimus
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,24,36263,DB01590,Everolimus
,12752317,Cmins,"Cmins averaged 4.3 +/- 2.4 and 7.2 +/- 4.2 ng/mL at 0.75 and 1.5 mg bid, indicating a 20% under-proportionality at the upper dose level.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[ng] / [ml],4.3,40943,DB01590,Everolimus
,12752317,Cmins,"Cmins averaged 4.3 +/- 2.4 and 7.2 +/- 4.2 ng/mL at 0.75 and 1.5 mg bid, indicating a 20% under-proportionality at the upper dose level.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[ng] / [ml],7.2,40944,DB01590,Everolimus
,12752317,AUC,"AUC was dose-proportional and stable over time, averaging 77 +/- 32 and 136 +/- 57 ng.h.mL-1 at the two dose levels.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[h·ng] / [ml],77,40945,DB01590,Everolimus
,12752317,AUC,"AUC was dose-proportional and stable over time, averaging 77 +/- 32 and 136 +/- 57 ng.h.mL-1 at the two dose levels.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[h·ng] / [ml],136,40946,DB01590,Everolimus
,19584690,trough level,"In a 12-month multicenter open-label study, cardiac transplant patients received everolimus (trough level 3-8 ng/mL) with reduced cyclosporine A (CsA) or MMF (3 g/day) with standard CsA, both with corticosteroids+/-induction therapy.",Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19584690/),[ng] / [ml],3-8,42949,DB01590,Everolimus
,24013904,progression-free survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,11.0,45577,DB01590,Everolimus
,24013904,overall survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,21.0,45578,DB01590,Everolimus
,19784839,T/C,Maximal antitumor effects (T/C of 0.04-0.35) were observed in both species after daily administration with similar C(max) and AUC values of unbound (free) RAD001.,Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19784839/),,0.04-0.35,46054,DB01590,Everolimus
,20975068,progression-free survival,"Median progression-free survival was 34 weeks (95% CI, 29.1 to 40.7 weeks).",Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975068/),weeks,34,48656,DB01590,Everolimus
,32005746,progression-free survival,The median progression-free survival and overall survival were 2.7 (1.8-4.2) and 9 (6.4-13.2) months.,"A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32005746/),month,2.7,49767,DB01590,Everolimus
,32005746,overall survival,The median progression-free survival and overall survival were 2.7 (1.8-4.2) and 9 (6.4-13.2) months.,"A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32005746/),month,9,49768,DB01590,Everolimus
,24861504,trough levels [C0],"Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0] 3-8 ng/mL and 5-15 ng/mL, respectively).","Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861504/),[ng] / [ml],3-8,50425,DB01590,Everolimus
,24861504,trough levels [C0],"Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0] 3-8 ng/mL and 5-15 ng/mL, respectively).","Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861504/),[ng] / [ml],5-15,50426,DB01590,Everolimus
,11557912,absorption rate constant,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),1/[h],6.07,52477,DB01590,Everolimus
,11557912,apparent clearance,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),[l] / [h],8.8,52478,DB01590,Everolimus
,11557912,apparent central distribution volume,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),l,110,52479,DB01590,Everolimus
,26181632,half-life,Subcutaneously administered EC0565 in rats displayed good bioavailability and a relatively long half-life (~12 h).,Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26181632/),h,12,53303,DB01590,Everolimus
,27206639,MTD,The MTD of everolimus in combination with cisplatin and radiotherapy has been defined as 5 mg/day.,A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206639/),[mg] / [d],5,55818,DB01590,Everolimus
,25103371,area under the curve,"Patients received carboplatin (area under the curve = 2 mg/ml/min; 3 weeks on, 1 week off), cetuximab (with a loading dose of 400 mg/m(2) and then 250 mg/m(2) weekly), and dose-escalating everolimus (2.5, 5.0, 7.5, and 10 mg/day) with a 3+3 design.",Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),[mg] / [min·ml],2,56266,DB01590,Everolimus
,25103371,objective response rate (RR),The objective response rate (RR) was 61.5% (all partial responses).,Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),%,61,56267,DB01590,Everolimus
,25103371,Progression-free survival (PFS),Progression-free survival (PFS) was 8.15 months.,Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),month,8.15,56268,DB01590,Everolimus
,21177764,time on study,Median time on study was 104 days (range 17-300).,Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177764/),d,104,60784,DB01590,Everolimus
,23131698,apparent clearance,Estimation of EVE apparent clearance (3.33 ± 0.20 L/h) and apparent volume of distribution (146 ± 33 L) were in accordance with previously published data.,"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23131698/),[l] / [h],3.33,60994,DB01590,Everolimus
,23131698,apparent volume of distribution,Estimation of EVE apparent clearance (3.33 ± 0.20 L/h) and apparent volume of distribution (146 ± 33 L) were in accordance with previously published data.,"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23131698/),l,146,60995,DB01590,Everolimus
,26294908,PFS,"Median PFS and OS were 33 (95%CI: 8-56) and 30 (95%CI: 15-45) weeks, respectively.",Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26294908/),weeks,33,61291,DB01590,Everolimus
,26294908,OS,"Median PFS and OS were 33 (95%CI: 8-56) and 30 (95%CI: 15-45) weeks, respectively.",Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26294908/),weeks,30,61292,DB01590,Everolimus
,19426700,t(1/2),The elimination half-life was comparable (t(1/2)=5.3h vs. t(1/2)=4h).,Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19426700/),h,5.3,61757,DB01590,Everolimus
,19426700,t(1/2),The elimination half-life was comparable (t(1/2)=5.3h vs. t(1/2)=4h).,Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19426700/),h,4,61758,DB01590,Everolimus
,21079958,progression-free survival (PFS),Median progression-free survival (PFS) for the doublet therapy was 6.0 months (0.5 to 32+ months) and 5.5 months (0.8 to 27+ months) for the triplet therapy.,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),month,6.0,63224,DB01590,Everolimus
,21079958,progression-free survival (PFS),Median progression-free survival (PFS) for the doublet therapy was 6.0 months (0.5 to 32+ months) and 5.5 months (0.8 to 27+ months) for the triplet therapy.,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),month,5.5,63225,DB01590,Everolimus
,21079958,Systemic exposure,Systemic exposure of everolimus was significantly higher in combination with erlotinib (476 ± 161 ng h/mL) compared to when given alone (393 ± 156 ng h/mL; P = 0.020).,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),[h·ng] / [ml],476,63226,DB01590,Everolimus
,21079958,Systemic exposure,Systemic exposure of everolimus was significantly higher in combination with erlotinib (476 ± 161 ng h/mL) compared to when given alone (393 ± 156 ng h/mL; P = 0.020).,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),[h·ng] / [ml],393,63227,DB01590,Everolimus
,31763512,trough levels,"Furthermore, EVE trough levels were higher in men than women (19.4 versus 15.4 ng/mL, p = 0.01).","Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31763512/),[ng] / [ml],19.4,63931,DB01590,Everolimus
,31763512,trough levels,"Furthermore, EVE trough levels were higher in men than women (19.4 versus 15.4 ng/mL, p = 0.01).","Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31763512/),[ng] / [ml],15.4,63932,DB01590,Everolimus
,26174223,time receiving drug,Mean time receiving drug was 99 days.,A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26174223/),d,99,65360,DB01590,Everolimus
,26375845,AUC,Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients.,"Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),,4,67934,DB01590,Everolimus
,26375845,time to progression,"The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months).","Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),month,2.5,67935,DB01590,Everolimus
,26375845,overall survival,"The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months).","Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),month,12.5,67936,DB01590,Everolimus
,26951309,progression-free survival,"After 67 events, stratified analysis revealed that median progression-free survival was significantly shorter for apitolisib than for everolimus (3.7 v 6.1 months; hazard ratio, 2.12 [95% CI, 1.23 to 3.63; P < .01]); apitolisib was not favored in any stratification subgroup.","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,3.7,70597,DB01590,Everolimus
,26951309,progression-free survival,"After 67 events, stratified analysis revealed that median progression-free survival was significantly shorter for apitolisib than for everolimus (3.7 v 6.1 months; hazard ratio, 2.12 [95% CI, 1.23 to 3.63; P < .01]); apitolisib was not favored in any stratification subgroup.","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,6.1,70598,DB01590,Everolimus
,26951309,overall survival,"Median overall survival was not significantly different but trended in favor of everolimus (16.5 v 22.8 months; hazard ratio, 1.77 [95% CI, 0.97 to 3.24; P = .06]).","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,16.5,70599,DB01590,Everolimus
,26951309,overall survival,"Median overall survival was not significantly different but trended in favor of everolimus (16.5 v 22.8 months; hazard ratio, 1.77 [95% CI, 0.97 to 3.24; P = .06]).","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,22.8,70600,DB01590,Everolimus
,26951309,objective response rate,The objective response rate was 7.1% for apitolisib and 11.6% for everolimus.,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),%,7.1,70601,DB01590,Everolimus
,26951309,objective response rate,The objective response rate was 7.1% for apitolisib and 11.6% for everolimus.,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),%,11.6,70602,DB01590,Everolimus
,26714164,central volume of distribution,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),l,2.1,72701,DB01590,Everolimus
,26714164,peripheral volume of distribution,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),l,1.3,72702,DB01590,Everolimus
,26714164,intercompartment clearance,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),[l] / [day],0.36,72703,DB01590,Everolimus
,26714164,elimination half-life,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),d,11.8,72704,DB01590,Everolimus
,26714164,clearance,Typical clearance was 0.22 l day(-1) (19%) and its value was increased with tumour size.,Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),[l] / [day],0.22,72705,DB01590,Everolimus
,17947729,clearance,"At the MTD of 5 mg/m2, the median everolimus clearance was 15.2 L/h/m2, with a plasma everolimus concentration-time area under the curve (AUC) from 0 to infinity of 239.6 ng/mL x h.",Phase I study of everolimus in pediatric patients with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947729/),[l] / [h·m2],15.2,76924,DB01590,Everolimus
,17947729,concentration-time area under the curve (AUC) from 0 to infinity,"At the MTD of 5 mg/m2, the median everolimus clearance was 15.2 L/h/m2, with a plasma everolimus concentration-time area under the curve (AUC) from 0 to infinity of 239.6 ng/mL x h.",Phase I study of everolimus in pediatric patients with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947729/),[ng] / [h·ml],239.6,76925,DB01590,Everolimus
,17947729,AUCs,"Significant inhibition of mTOR pathway signaling was observed in PBMCs from patients achieving AUCs 200 ng/mL x h, equivalent to dosages of 3 to 5 mg/m2 of everolimus.",Phase I study of everolimus in pediatric patients with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947729/),[ng] / [h·ml],200,76926,DB01590,Everolimus
,32335374,t1/2z,"Single dosing of vorolanib demonstrated dose-proportional increases in the Cmax and AUC, and observed short t1/2z ranging from 4.74±1.44 to 12.89±7.49 h.",Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32335374/),h,4.74,77239,DB01590,Everolimus
,32335374,t1/2z,"Single dosing of vorolanib demonstrated dose-proportional increases in the Cmax and AUC, and observed short t1/2z ranging from 4.74±1.44 to 12.89±7.49 h.",Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32335374/),h,12.89,77240,DB01590,Everolimus
,31376625,trough EVR level,The trough EVR level in both groups was maintained within 3-8 ng/mL during the perioperative period.,Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376625/),[ng] / [ml],3-8,78330,DB01590,Everolimus
,21168674,time after transplantation,"Mean patient age was 58.2 ± 8.8 years, and mean time after transplantation was 2.3 ± 4.0 years (range, 0.2-13.0 years).",Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),years,2.3,78356,DB01590,Everolimus
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.5,78357,DB01590,Everolimus
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.8,78358,DB01590,Everolimus
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],45.2,78359,DB01590,Everolimus
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],65.2,78360,DB01590,Everolimus
,31752553,en,"The average particle size of the micelles was (8.74 ± 0.21) nm, the encapsulation efficiency and drug loading were (90.12 ± 1.18)% and (2.14 ± 0.028)%, while the average particle size of the nanosuspension was (156.47 ± 1.10) nm, and the drug loading was (16.51 ± 0.21)%, respectively.",Preparation and study of two kinds of ophthalmic nano-preparations of everolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31752553/),%,90.12,79170,DB01590,Everolimus
,31752553,particle size,"The average particle size of the micelles was (8.74 ± 0.21) nm, the encapsulation efficiency and drug loading were (90.12 ± 1.18)% and (2.14 ± 0.028)%, while the average particle size of the nanosuspension was (156.47 ± 1.10) nm, and the drug loading was (16.51 ± 0.21)%, respectively.",Preparation and study of two kinds of ophthalmic nano-preparations of everolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31752553/),,156.,79171,DB01590,Everolimus
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],3 and 15,83849,DB01590,Everolimus
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],100-300,83850,DB01590,Everolimus
,27169792,AUC0-24,"Patients who required a dose reduction (n = 18) due to toxicity at any time during treatment had significant higher everolimus exposures [mean AUC0-24 (SD) 600 (274) vs. 395 (129) µg h/L, P = 0.008] than patients without a dose reduction (n = 22).",Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169792/),[h·μg] / [l],600,96778,DB01590,Everolimus
,27169792,AUC0-24,"Patients who required a dose reduction (n = 18) due to toxicity at any time during treatment had significant higher everolimus exposures [mean AUC0-24 (SD) 600 (274) vs. 395 (129) µg h/L, P = 0.008] than patients without a dose reduction (n = 22).",Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169792/),[h·μg] / [l],395,96779,DB01590,Everolimus
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,50.0,98403,DB01590,Everolimus
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,22.2,98404,DB01590,Everolimus
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,16.7,98405,DB01590,Everolimus
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,40.0,98406,DB01590,Everolimus
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,61.1,98407,DB01590,Everolimus
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,58.3,98408,DB01590,Everolimus
,17175302,trough level (C0),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],7.9,103909,DB01590,Everolimus
,17175302,area under the curve over a dosing interval (AUC),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],132,103910,DB01590,Everolimus
,17175302,C0,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.4,103911,DB01590,Everolimus
,17175302,AUC,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],134,103912,DB01590,Everolimus
,17175302,C0,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.3,103913,DB01590,Everolimus
,17175302,Cmax,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],10.4,103914,DB01590,Everolimus
,17175302,AUC,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],58,103915,DB01590,Everolimus
,17175302,C0,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.0,103916,DB01590,Everolimus
,17175302,Cmax,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.2,103917,DB01590,Everolimus
,17175302,AUC,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],49,103918,DB01590,Everolimus
,22182476,time to platelet recovery,RAD001/CsA caused a more pronounced reduction of platelet counts to median 2 × 10(9)/L (range: 0-21 × 10(9)/L) and longer time to platelet recovery of 21 days (range: 14-24 days) compared with MMF/CsA.,Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22182476/),d,21,105054,DB01590,Everolimus
,18332470,Terminal half-life,"Terminal half-life was 30 hours (range, 26 to 38 hours).",Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18332470/),h,30,106887,DB01590,Everolimus
,12829916,C(min) (trough level),"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],4.7,107786,DB01590,Everolimus
,12829916,peak concentration,"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],13.5,107787,DB01590,Everolimus
,12829916,area under the concentration-time curve (AUC),"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[h·ng] / [ml],77,107788,DB01590,Everolimus
,12829916,apparent oral clearance,"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[l] / [h·m2],10.2,107789,DB01590,Everolimus
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.9,107790,DB01590,Everolimus
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.4,107791,DB01590,Everolimus
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.1,107792,DB01590,Everolimus
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],156,107793,DB01590,Everolimus
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],83,107794,DB01590,Everolimus
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],69,107795,DB01590,Everolimus
,22624503,area under the blood concentration-time curve from time zero to 12 hours (AUC(12)),Everolimus blood concentrations were analysed in whole blood using liquid chromatography-tandem mass spectrometry during routine therapeutic drug monitoring targeting an area under the blood concentration-time curve from time zero to 12 hours (AUC(12)) of 120 μg · h/L.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114932,DB01590,Everolimus
,22624503,AUC(12),Maintaining everolimus systemic exposure at an AUC(12) of 120 μg · h/L resulted in low rejection rates but considerable numbers of adverse events and toxicity.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114933,DB01590,Everolimus
,22624503,oral clearance,Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[l] / [h],17.9,114934,DB01590,Everolimus
,22624503,volume of distribution of the central compartment after oral administration [V(1)/F],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),l,148,114935,DB01590,Everolimus
,22624503,first-order absorption rate constant [k(a)],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),1/[h],7.36,114936,DB01590,Everolimus
,26919549,concentrations,"In TAC (STN → MPS) group, dose-adjusted TAC concentrations decreased from baseline to first week (2.3 ± 1.1 versus 1.5 ± 1.0 ng·mL·mg, P < 0.05).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),,1.5,121430,DB01590,Everolimus
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,3.,121431,DB01590,Everolimus
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,1.9,121432,DB01590,Everolimus
,33547201,RP2D,"The RP2D of ribociclib and everolimus was 120 and 1.2 mg/m2 for 21 and 28 days, respectively.",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),[mg] / [m2],120,122370,DB01590,Everolimus
,33547201,RP2D,"The RP2D of ribociclib and everolimus was 120 and 1.2 mg/m2 for 21 and 28 days, respectively.",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),[mg] / [m2],1.2,122371,DB01590,Everolimus
,33547201,tumor-to-plasma ratio,"The mean tumor-to-plasma ratio of ribociclib was 19.8 (range, 2.22-53.4).",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),,19.8,122372,DB01590,Everolimus
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],21,126057,DB01590,Everolimus
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],47,126058,DB01590,Everolimus
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],115,126059,DB01590,Everolimus
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],392,126060,DB01590,Everolimus
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,32,126061,DB01590,Everolimus
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,37,126062,DB01590,Everolimus
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126063,DB01590,Everolimus
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126064,DB01590,Everolimus
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126065,DB01590,Everolimus
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126066,DB01590,Everolimus
,21232120,Tmax,"Everolimus was absorbed rapidly; median Tmax was 3 h (range, 1-4) and 2 h (range, 0.9-6) in the 5 and 10 mg/day groups, respectively.",Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21232120/),h,3,128741,DB01590,Everolimus
,21232120,Tmax,"Everolimus was absorbed rapidly; median Tmax was 3 h (range, 1-4) and 2 h (range, 0.9-6) in the 5 and 10 mg/day groups, respectively.",Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21232120/),h,2,128742,DB01590,Everolimus
,25017487,trough concentration,Everolimus exposure is unaffected when tacrolimus exposure is down-titrated within the trough concentration range of 1.5-7 ng/mL.,The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25017487/),[ng] / [ml],1.5-7,130074,DB01590,Everolimus
,20040005,C(max),Individual C(max) ranged from 0.17 to 2.40 ng/mL and occurred between 0.07 and 1.88 hours across all dose levels.,Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040005/),[ng] / [ml],0.17 to 2.40,133395,DB01590,Everolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,150,134028,DB01590,Everolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,180,134029,DB01590,Everolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,88,134030,DB01590,Everolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,293,134031,DB01590,Everolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],0.86,134032,DB01590,Everolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],1.80,134033,DB01590,Everolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],0.50,134034,DB01590,Everolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],0.09,134035,DB01590,Everolimus
,21538783,peak drug levels,"After adjustment for the loaded dose, mean peak drug levels of the Cypher and Xience V stents were similar (0.0057 ng mL(-1) μg(-1) each) while the Endeavor (0.0100 ng mL(-1) μg(-1)) was higher, and the Nobori (0.0003 ng mL(-1) μg(-1)) was lower, compared with the Cypher and Xience V stents.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml·μg],0.0057,134036,DB01590,Everolimus
,21538783,peak drug levels,"After adjustment for the loaded dose, mean peak drug levels of the Cypher and Xience V stents were similar (0.0057 ng mL(-1) μg(-1) each) while the Endeavor (0.0100 ng mL(-1) μg(-1)) was higher, and the Nobori (0.0003 ng mL(-1) μg(-1)) was lower, compared with the Cypher and Xience V stents.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml·μg],0.0100,134037,DB01590,Everolimus
,21538783,peak drug levels,"After adjustment for the loaded dose, mean peak drug levels of the Cypher and Xience V stents were similar (0.0057 ng mL(-1) μg(-1) each) while the Endeavor (0.0100 ng mL(-1) μg(-1)) was higher, and the Nobori (0.0003 ng mL(-1) μg(-1)) was lower, compared with the Cypher and Xience V stents.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml·μg],0.0003,134038,DB01590,Everolimus
,10551636,half-life,"The drug was absorbed within 2 hr and displayed a 16-19-hr half-life, which is shorter than that of rapamycin.",A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551636/),h,16-19-,136171,DB01590,Everolimus
,12777861,half-life,"Because the subsequent pharmacokinetic analysis indicated rapid everolimus absorption, distribution, and clearance in mice (with a half-life of 3 to 6 hr and maximum drug blood concentration reached after 0.5 to 1 hr), treatment was changed to a twice-daily regimen.",Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12777861/),h,3 to 6,138777,DB01590,Everolimus
,17431753,clearance rate,Everolimus exhibited a high clearance rate that was limited to the hepatic blood flow (47.2 ml/min/kg).,Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431753/),[ml] / [kg·min],47.2,140070,DB01590,Everolimus
,17431753,hepatic blood flow,Everolimus exhibited a high clearance rate that was limited to the hepatic blood flow (47.2 ml/min/kg).,Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431753/),[ml] / [kg·min],47.2,140071,DB01590,Everolimus
,17431753,oral bioavailability,"The oral bioavailability value, as estimated with the PBPK, was 12% and was similar to the value obtained by non-compartmental analysis.",Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431753/),%,12,140072,DB01590,Everolimus
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.4,143176,DB01590,Everolimus
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.5,143177,DB01590,Everolimus
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.7,143178,DB01590,Everolimus
,24628014,L/D,EVR L/D was 3.4 ± 1.7 in LTxR receiving diltiazem (DILT) vs. 1.8 ± 1.1 ng/mL per mg/d in LTxR not receiving DILT (p <0.001).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],3.4,143179,DB01590,Everolimus
,24628014,L/D,EVR L/D was 3.4 ± 1.7 in LTxR receiving diltiazem (DILT) vs. 1.8 ± 1.1 ng/mL per mg/d in LTxR not receiving DILT (p <0.001).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],1.8,143180,DB01590,Everolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],40.50,144481,DB01590,Everolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.08,144482,DB01590,Everolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],43.00,144483,DB01590,Everolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.85,144484,DB01590,Everolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],56.75,144485,DB01590,Everolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],36.20,144486,DB01590,Everolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.83,144487,DB01590,Everolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],12.08,144488,DB01590,Everolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.77,144489,DB01590,Everolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],13.00,144490,DB01590,Everolimus
,21913034,C (max),PK analysis of everolimus demonstrated dose-proportional increases in C (max) (mean 91.9 ng/ml) and AUC(0-INF) (mean 680.5 h*ng/ml) at dose level 4.,A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913034/),[ng] / [ml],91.9,145668,DB01590,Everolimus
,21913034,AUC(0-INF),PK analysis of everolimus demonstrated dose-proportional increases in C (max) (mean 91.9 ng/ml) and AUC(0-INF) (mean 680.5 h*ng/ml) at dose level 4.,A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913034/),[h·ng] / [ml],680.5,145669,DB01590,Everolimus
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],5.2,149623,DB01590,Everolimus
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],9.4,149624,DB01590,Everolimus
<,14550821,trough levels,"We observed a significantly increased risk of acute rejection at everolimus trough levels <3 ng/ml, which constitutes the lower therapeutic concentration limit when everolimus is used with conventionally dosed cyclosporine.","Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],3,149625,DB01590,Everolimus
,14550821,troughs,Everolimus-related adverse events were manageable up to the highest troughs (22 ng/ml) observed in this population.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],22,149626,DB01590,Everolimus
,15785960,C (max),"During erythromycin coadministration, everolimus C (max) increased 2.0-fold (90% CI, 1.8-2.3) from 20+/-5 ng/ml to 40+/-10 ng/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[ng] / [ml],20,149749,DB01590,Everolimus
,15785960,C (max),"During erythromycin coadministration, everolimus C (max) increased 2.0-fold (90% CI, 1.8-2.3) from 20+/-5 ng/ml to 40+/-10 ng/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[ng] / [ml],40,149750,DB01590,Everolimus
,15785960,AUC,"Everolimus AUC increased 4.4-fold (90% CI, 3.5-5.4) from 116+/-37 ng h/ml to 524+/-225 ng h/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[h·ng] / [ml],116,149751,DB01590,Everolimus
,15785960,AUC,"Everolimus AUC increased 4.4-fold (90% CI, 3.5-5.4) from 116+/-37 ng h/ml to 524+/-225 ng h/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[h·ng] / [ml],524,149752,DB01590,Everolimus
,15785960,half-life,Everolimus half-life was prolonged by 39% from 32+/-6 h to 44+/-6 h.,Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),h,32,149753,DB01590,Everolimus
,15785960,half-life,Everolimus half-life was prolonged by 39% from 32+/-6 h to 44+/-6 h.,Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),h,44,149754,DB01590,Everolimus
,10594471,elimination half-life,The elimination half-life ranged from 24 to 35 h across the five highest dose groups.,Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594471/),h,24 to 35,153257,DB01590,Everolimus
,18926156,T(max),"Across all dose levels, individual T(max) values ranged from 0.13 and 2.17 hours; individual C(max) ranged from 0.14 to 2.79 ng/mL.",Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18926156/),h,0.13,154519,DB01590,Everolimus
,18926156,T(max),"Across all dose levels, individual T(max) values ranged from 0.13 and 2.17 hours; individual C(max) ranged from 0.14 to 2.79 ng/mL.",Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18926156/),h,2.17,154520,DB01590,Everolimus
,18926156,C(max),"Across all dose levels, individual T(max) values ranged from 0.13 and 2.17 hours; individual C(max) ranged from 0.14 to 2.79 ng/mL.",Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18926156/),[ng] / [ml],0.14 to 2.79,154521,DB01590,Everolimus
,18812562,steady-state minimum concentration (C(min)),Satisfactory steady-state minimum concentration (C(min)) of everolimus was achieved (approximately 5 ng/mL).,Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],5,154970,DB01590,Everolimus
,18812562,C(min),"At that time, the everolimus C(min) averaged approximately 3 ng/mL.",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],3,154971,DB01590,Everolimus
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154972,DB01590,Everolimus
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154973,DB01590,Everolimus
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154974,DB01590,Everolimus
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154975,DB01590,Everolimus
,24655978,AUC0-12,"The mean (SD) AUC0-12 for EVL and EVL plus atorvastatin was 155.9 (41.6) ng·h/mL and 151.3 (51.4) ng·h/mL, respectively (P > .05; paired t test).",Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655978/),[h·ng] / [ml],155.9,160864,DB01590,Everolimus
,24655978,AUC0-12,"The mean (SD) AUC0-12 for EVL and EVL plus atorvastatin was 155.9 (41.6) ng·h/mL and 151.3 (51.4) ng·h/mL, respectively (P > .05; paired t test).",Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655978/),[h·ng] / [ml],151.3,160865,DB01590,Everolimus
,24923538,platelet nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,0 × 10(9),162089,DB01590,Everolimus
,24923538,leukocyte nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,1.0 × 10(9),162090,DB01590,Everolimus
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [l],19.1,162091,DB01590,Everolimus
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[mg] / [l],.3,162092,DB01590,Everolimus
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [h·l],325,162093,DB01590,Everolimus
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[ng] / [h·l],29.6,162094,DB01590,Everolimus
,26990259,trough concentration,To examine whether a trough concentration of everolimus in the therapeutic range of 3-5 ng/mL affects the pharmacokinetics of tacrolimus in renal transplant patients.,Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26990259/),[ng] / [ml],3-5,175895,DB01590,Everolimus
> or =,20517177,target trough levels,"Data were from a prospective, multicenter, open-label, randomized, exploratory 6-month study of 92 renal transplant patients treated de novo with concentration-controlled Evl (target trough levels > or =3 ng/mL) plus low-dose Tac or Evl plus standard-dose Tac; both groups received basiliximab and corticosteroids.",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180909,DB01590,Everolimus
less,20517177,Evl,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180910,DB01590,Everolimus
less,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180911,DB01590,Everolimus
less,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3 to 8,180912,DB01590,Everolimus
more,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],8,180913,DB01590,Everolimus
more,20517177,Evl trough level,Evl trough level of more than or equal to 3 ng/mL was associated with significantly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180914,DB01590,Everolimus
less,20517177,trough level,Evl trough level of more than or equal to 3 ng/mL was associated with significantly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180915,DB01590,Everolimus
> or =,20517177,trough levels,Evl trough levels > or =3 ng/mL plus Tac are associated with low rates of BPAR without adversely affecting renal function.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180916,DB01590,Everolimus
,20003043,survival,"In the DA to LEW model, combining a nonefficacious dose of AEB (10 mg/kg b.i.d.) with a nonefficacious dose of cyclosporine, everolimus or FTY720 led to prolonged median survival times (26 days, >68 days and >68 days, respectively).","Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003043/),d,26,182384,DB01590,Everolimus
>,20003043,survival,"In the DA to LEW model, combining a nonefficacious dose of AEB (10 mg/kg b.i.d.) with a nonefficacious dose of cyclosporine, everolimus or FTY720 led to prolonged median survival times (26 days, >68 days and >68 days, respectively).","Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003043/),d,68,182385,DB01590,Everolimus
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],44.9,185175,DB01590,Everolimus
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],30.5,185176,DB01590,Everolimus
,27798513,trough level (Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],3-8,195366,DB01590,Everolimus
,27798513,Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],2-5,195367,DB01590,Everolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],7.2,195368,DB01590,Everolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.9,195369,DB01590,Everolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.5,195370,DB01590,Everolimus
,27798513,Ctrough,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.7,195371,DB01590,Everolimus
,27798513,AUC0-12h,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [h·ml],106,195372,DB01590,Everolimus
,27798513,Caverage,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],8.8,195373,DB01590,Everolimus
,27798513,Cmax,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],19.2,195374,DB01590,Everolimus
,27798513,apparent Half-life,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),h,11.7,195375,DB01590,Everolimus
,27798513,total body clearance,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[l] / [h],0.39,195376,DB01590,Everolimus
,23913602,inflammation score,"At 28 days, inflammation was significantly less in the EES group as compared to the R-ZES group (inflammation score: 1.59 ± 0.52 vs 2.22 ± 0.69, respectively; P=.044), with no differences observed at 60 days.",Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23913602/),,1.59,195520,DB01590,Everolimus
,23913602,inflammation score,"At 28 days, inflammation was significantly less in the EES group as compared to the R-ZES group (inflammation score: 1.59 ± 0.52 vs 2.22 ± 0.69, respectively; P=.044), with no differences observed at 60 days.",Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23913602/),,2.22,195521,DB01590,Everolimus
,22051872,maximum observed everolimus blood concentrations (C(max)),"Following the procedure, the maximum observed everolimus blood concentrations (C(max)) varied from 1.83 ± 0.05 ng/mL after implantation of a single 80-mm stent to 4.66 ± 1.78 ng/mL after implantation of two 100-mm stents.",Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),[ng] / [ml],1.83,197445,DB01590,Everolimus
,22051872,maximum observed everolimus blood concentrations (C(max)),"Following the procedure, the maximum observed everolimus blood concentrations (C(max)) varied from 1.83 ± 0.05 ng/mL after implantation of a single 80-mm stent to 4.66 ± 1.78 ng/mL after implantation of two 100-mm stents.",Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),[ng] / [ml],4.66,197446,DB01590,Everolimus
,22051872,time to peak concentration (T(max)),The mean time to peak concentration (T(max)) varied from 6.8 hours to 35 hours.,Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),h,6.8,197447,DB01590,Everolimus
,22051872,time to peak concentration (T(max)),The mean time to peak concentration (T(max)) varied from 6.8 hours to 35 hours.,Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),h,35,197448,DB01590,Everolimus
,20972652,overall response rate,Two patients with diffuse large B cell lymphoma and two patients with follicular lymphomas achieved objective responses with an overall response rate of 31% (4/13).,Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20972652/),%,31,199202,DB01590,Everolimus
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],80.3,199420,DB01590,Everolimus
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],78.5,199421,DB01590,Everolimus
,24521776,AUC0-24,"Mean rosuvastatin AUC0-24 was 157±61.7 ng*h/mL, approximately threefold higher than reported in the literature for nontransplants.",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·ng] / [ml],157,199422,DB01590,Everolimus
,20335831,Cmin,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),[ng] / [ml],11.1,200282,DB01590,Everolimus
,20335831,Cmin,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),[ng] / [ml],9.4,200283,DB01590,Everolimus
,20335831,area under the curves,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),,162,200284,DB01590,Everolimus
,20335831,area under the curves,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),,171,200285,DB01590,Everolimus
,30906563,blood concentrations,"The median (range) everolimus blood concentrations on day 8 after starting everolimus administration and just before discontinuation or dose reduction were 15.3 (8.1-28.0) ng/mL and 14.8 (6.4-58.4) ng/mL, respectively, with no significant difference between these values (P = 0.3594).",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),[ng] / [ml],15.3,200885,DB01590,Everolimus
,30906563,blood concentrations,"The median (range) everolimus blood concentrations on day 8 after starting everolimus administration and just before discontinuation or dose reduction were 15.3 (8.1-28.0) ng/mL and 14.8 (6.4-58.4) ng/mL, respectively, with no significant difference between these values (P = 0.3594).",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),[ng] / [ml],14.8,200886,DB01590,Everolimus
,30906563,blood concentrations,"Patients (n = 6) with discontinuation or dose reduction following adverse events in everolimus therapy had significantly higher blood concentrations than patients (n = 4) with dose maintenance on both day 8 (median, 18.0 vs 8.2 ng/mL; P = 0.0139) and just before discontinuation or dose reduction (median, 22.9 vs 9.7 ng/mL; P = 0.0142).",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),[ng] / [ml],18,200887,DB01590,Everolimus
,30906563,blood concentrations,"Patients (n = 6) with discontinuation or dose reduction following adverse events in everolimus therapy had significantly higher blood concentrations than patients (n = 4) with dose maintenance on both day 8 (median, 18.0 vs 8.2 ng/mL; P = 0.0139) and just before discontinuation or dose reduction (median, 22.9 vs 9.7 ng/mL; P = 0.0142).",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),[ng] / [ml],8.2,200888,DB01590,Everolimus
,30906563,blood concentrations,"Patients (n = 6) with discontinuation or dose reduction following adverse events in everolimus therapy had significantly higher blood concentrations than patients (n = 4) with dose maintenance on both day 8 (median, 18.0 vs 8.2 ng/mL; P = 0.0139) and just before discontinuation or dose reduction (median, 22.9 vs 9.7 ng/mL; P = 0.0142).",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),ng,22.9,200889,DB01590,Everolimus
,30906563,blood concentrations,"Patients (n = 6) with discontinuation or dose reduction following adverse events in everolimus therapy had significantly higher blood concentrations than patients (n = 4) with dose maintenance on both day 8 (median, 18.0 vs 8.2 ng/mL; P = 0.0139) and just before discontinuation or dose reduction (median, 22.9 vs 9.7 ng/mL; P = 0.0142).",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),ng,9.7,200890,DB01590,Everolimus
,30906563,TTF,"Median TTF and PFS of the total patients (n = 10) were 96 days (95% confidence interval [CI], 26-288) and 235 days (95% CI, 28-291), respectively.",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),d,96,200891,DB01590,Everolimus
,30906563,PFS,"Median TTF and PFS of the total patients (n = 10) were 96 days (95% confidence interval [CI], 26-288) and 235 days (95% CI, 28-291), respectively.",Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906563/),d,235,200892,DB01590,Everolimus
,20137762,C(max),Coadministration of everolimus decreased sotrastaurin C(max) from 638 +/- 295 to 539 +/- 211 ng/ml yielding a combination/ monotherapy ratio (90% confidence interval) of 0.87 (0.76 - 1.00).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],638,210638,DB01590,Everolimus
,20137762,C(max),Coadministration of everolimus decreased sotrastaurin C(max) from 638 +/- 295 to 539 +/- 211 ng/ml yielding a combination/ monotherapy ratio (90% confidence interval) of 0.87 (0.76 - 1.00).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],539,210639,DB01590,Everolimus
,20137762,total AUC,Sotrastaurin total AUC was not altered by everolimus with values of 3660 +/- 1853 versus 3630 +/- 2006 ng*h/ml and a ratio of 1.00 (0.88 - 1.13).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],3660,210640,DB01590,Everolimus
,20137762,total AUC,Sotrastaurin total AUC was not altered by everolimus with values of 3660 +/- 1853 versus 3630 +/- 2006 ng*h/ml and a ratio of 1.00 (0.88 - 1.13).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],3630,210641,DB01590,Everolimus
,20137762,C(max),Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],15,210642,DB01590,Everolimus
,20137762,C(max),Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],16,210643,DB01590,Everolimus
,20137762,total AUC,Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],114,210644,DB01590,Everolimus
,20137762,total AUC,Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],137,210645,DB01590,Everolimus
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],5.2,222537,DB01590,Everolimus
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],9.4,222538,DB01590,Everolimus
> or =,15575918,trough levels,Biopsy-proven acute rejection (BPAR) was reduced with everolimus trough levels > or =3 ng/mL.,Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],3,222539,DB01590,Everolimus
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),[ml] / [kg·min],50,223122,DB01590,Everolimus
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223123,DB01590,Everolimus
,19790241,apparent intestinal,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223124,DB01590,Everolimus
,19790241,hepatic extraction,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,13,223125,DB01590,Everolimus
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.829,223126,DB01590,Everolimus
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.215,223127,DB01590,Everolimus
,24057042,MTD,"The MTD of the combination was 1,250 mg of lapatinib and 5 mg of everolimus once daily.",Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24057042/),mg,"1,250",223212,DB01590,Everolimus
,22878749,overall response rate,"One patient had a partial response to erlotinib/HCQ, for an overall response rate of 5% (95% confidence interval, 1-25).",A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22878749/),%,5,230952,DB01590,Everolimus
,27661398,apparent oral clearance,Everolimus pharmacokinetics was best described by a 2-compartment model with population mean estimates of apparent oral clearance of 10.0 L/h and an interindividual variability of 42.4%.,Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),[l] / [h],10.0,231150,DB01590,Everolimus
,27661398,trough concentration,The predicted trough concentration in patients who terminated everolimus treatment owing to adverse drug reactions (ADRs) was significantly higher than in patients who stopped the treatment owing to disease progression or other reasons (27.6 ± 3.1 versus 15.7 ± 2.3 ng/mL; mean ± SEM).,Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),[ng] / [ml],27.6,231151,DB01590,Everolimus
,27661398,trough concentration,The predicted trough concentration in patients who terminated everolimus treatment owing to adverse drug reactions (ADRs) was significantly higher than in patients who stopped the treatment owing to disease progression or other reasons (27.6 ± 3.1 versus 15.7 ± 2.3 ng/mL; mean ± SEM).,Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),[ng] / [ml],15.7,231152,DB01590,Everolimus
,27661398,time-to-treatment failure,"Patients who terminated the treatment owing to ADRs had significantly shorter time-to-treatment failure than other patients (112 versus 187 days, median).",Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),d,112,231153,DB01590,Everolimus
,27661398,time-to-treatment failure,"Patients who terminated the treatment owing to ADRs had significantly shorter time-to-treatment failure than other patients (112 versus 187 days, median).",Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),d,187,231154,DB01590,Everolimus
,32438078,Ctrough,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],30-61,235704,DB01590,Everolimus
,32438078,Cpeak,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],143-449,235705,DB01590,Everolimus
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-13,235706,DB01590,Everolimus
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-16,235707,DB01590,Everolimus
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-11,235708,DB01590,Everolimus
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],5-17,235709,DB01590,Everolimus
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],600,237179,DB01590,Everolimus
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],900,237180,DB01590,Everolimus
,20683390,elimination half-life,The elimination half-life of sotrastaurin averages 6 hours.,Overview of sotrastaurin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),h,6,237181,DB01590,Everolimus
,24908540,response rate,The response rate at the MDT was 1/15 (7%) while the progression free survival for the MTD was 7 months (95% confidence interval (CI) 2.2-11 months).,A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24908540/),,1,238101,DB01590,Everolimus
,24908540,progression free survival,The response rate at the MDT was 1/15 (7%) while the progression free survival for the MTD was 7 months (95% confidence interval (CI) 2.2-11 months).,A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24908540/),month,7,238102,DB01590,Everolimus
,10220493,systemic clearance,"After i.v. administration of 1 mg/kg SDZ-RAD or rapamycin, the area under the concentration curve (AUC) for rapamycin was twice that of SDZ-RAD, resulting in a systemic clearance of 6.2 ml/min and 3.0 ml/min for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[ml] / [min],6.2,238419,DB01590,Everolimus
,10220493,systemic clearance,"After i.v. administration of 1 mg/kg SDZ-RAD or rapamycin, the area under the concentration curve (AUC) for rapamycin was twice that of SDZ-RAD, resulting in a systemic clearance of 6.2 ml/min and 3.0 ml/min for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[ml] / [min],3.0,238420,DB01590,Everolimus
,10220493,AUC for oral absorption,"However, the AUC for oral absorption was similar for the two compounds: 140 and 172 ng*h/ml for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[h·ng] / [ml],140,238421,DB01590,Everolimus
,10220493,AUC for oral absorption,"However, the AUC for oral absorption was similar for the two compounds: 140 and 172 ng*h/ml for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[h·ng] / [ml],172,238422,DB01590,Everolimus
,10220493,absolute oral bioavailability,"Because blood clearance was faster for SDZ-RAD after i.v. administration, the absolute oral bioavailability for SDZ-RAD was 16% compared with 10% for rapamycin.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),%,16,238423,DB01590,Everolimus
,10220493,absolute oral bioavailability,"Because blood clearance was faster for SDZ-RAD after i.v. administration, the absolute oral bioavailability for SDZ-RAD was 16% compared with 10% for rapamycin.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),%,10,238424,DB01590,Everolimus
,14629289,Cmin,Everolimus Cmin averaged 9-11 ng/mL in the immediate cyclosporine group over the first 3 months.,Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],9-11,240928,DB01590,Everolimus
,14629289,Cmins,"In the delayed cyclosporine group, average everolimus Cmins were significantly lower by 2.9-fold in the absence vs. presence of cyclosporine: 2.9 +/- 2.8 vs. 8.3 +/- 3.7 ng/mL (p < 0.001).",Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],2.9,240929,DB01590,Everolimus
,14629289,Cmins,"In the delayed cyclosporine group, average everolimus Cmins were significantly lower by 2.9-fold in the absence vs. presence of cyclosporine: 2.9 +/- 2.8 vs. 8.3 +/- 3.7 ng/mL (p < 0.001).",Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],8.3,240930,DB01590,Everolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],49,242441,DB01590,Everolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],638,242442,DB01590,Everolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],28,242443,DB01590,Everolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],318,242444,DB01590,Everolimus
,10221478,trough levels,RAD and CsA day-14 trough levels in the staggered group were the same or lower than trough levels in animals treated with either drug alone (RAD 27+/-3/Neoral 815+/-67 ng/ml).,"Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],27,242445,DB01590,Everolimus
,10221478,trough levels,RAD and CsA day-14 trough levels in the staggered group were the same or lower than trough levels in animals treated with either drug alone (RAD 27+/-3/Neoral 815+/-67 ng/ml).,"Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],815,242446,DB01590,Everolimus
,30259313,Ctrough,"Among 44 evaluable patients, the geometric mean (GM) Ctrough was higher in patients with toxicity compared to patients without (17.4 versus 12.3 μg/L (p = 0.02)).",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],17.4,242948,DB01590,Everolimus
,30259313,Ctrough,"Among 44 evaluable patients, the geometric mean (GM) Ctrough was higher in patients with toxicity compared to patients without (17.4 versus 12.3 μg/L (p = 0.02)).",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],12.3,242949,DB01590,Everolimus
>,30259313,Ctrough,The optimal cut-off value to predict toxicity was Ctrough > 19.2 μg/L.,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],19.2,242950,DB01590,Everolimus
,30259313,Ctrough,GM Ctrough of patients with and without progressive disease (PD) within 3 months was not significantly different (12.0 versus 15.2 μg/L (p = 0.118)).,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],12.0,242951,DB01590,Everolimus
,30259313,Ctrough,GM Ctrough of patients with and without progressive disease (PD) within 3 months was not significantly different (12.0 versus 15.2 μg/L (p = 0.118)).,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],15.2,242952,DB01590,Everolimus
,30259313,PFS,"Patients with <11% versus >11% decrease in SULpeak high at day 14 had a median PFS of 90 days versus 411 days, respectively (p = 0.0013) and more frequently had PD within 3 months: 70 vs 11%, respectively.",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),d,90,242953,DB01590,Everolimus
,30259313,PFS,"Patients with <11% versus >11% decrease in SULpeak high at day 14 had a median PFS of 90 days versus 411 days, respectively (p = 0.0013) and more frequently had PD within 3 months: 70 vs 11%, respectively.",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),d,411,242954,DB01590,Everolimus
,28923619,trough level,Target trough level of EVL was 3-8 ng/mL.,Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],3-8,249097,DB01590,Everolimus
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],"309 to 1,896",249098,DB01590,Everolimus
,28923619,area under the receiver operating characteristic curve (AUC),"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],"3,449",249099,DB01590,Everolimus
,28923619,C0,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],5.2,249100,DB01590,Everolimus
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],15.4,249101,DB01590,Everolimus
,28923619,AUC,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],99.7,249102,DB01590,Everolimus
,11719728,apparent clearance,The apparent clearance of everolimus was significantly reduced by 53% in subjects with moderate hepatic impairment compared with healthy subjects (9.1 +/- 3.1 versus 19.4 +/- 5.8 L/h).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),[l] / [h],9.1,251717,DB01590,Everolimus
,11719728,apparent clearance,The apparent clearance of everolimus was significantly reduced by 53% in subjects with moderate hepatic impairment compared with healthy subjects (9.1 +/- 3.1 versus 19.4 +/- 5.8 L/h).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),[l] / [h],19.4,251718,DB01590,Everolimus
,11719728,area under the blood concentration-time curve (AUC),This was manifested by a 115% higher area under the blood concentration-time curve (AUC) (245 +/- 91 versus 114 +/- 45 ng.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),ng,245,251719,DB01590,Everolimus
,11719728,area under the blood concentration-time curve (AUC),This was manifested by a 115% higher area under the blood concentration-time curve (AUC) (245 +/- 91 versus 114 +/- 45 ng.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),ng,114,251720,DB01590,Everolimus
,11719728,half-life,h/ml) and 84% prolonged half-life (79 +/- 42 versus 43 +/- 18 hours) in subjects with hepatic impairment.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),h,79,251721,DB01590,Everolimus
,11719728,half-life,h/ml) and 84% prolonged half-life (79 +/- 42 versus 43 +/- 18 hours) in subjects with hepatic impairment.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),h,43,251722,DB01590,Everolimus
,11719728,Protein binding,Protein binding was similar in the two groups (73.8% +/- 3.6% versus 73.5% +/- 2.4%).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),%,73.8,251723,DB01590,Everolimus
,11719728,Protein binding,Protein binding was similar in the two groups (73.8% +/- 3.6% versus 73.5% +/- 2.4%).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),%,73.5,251724,DB01590,Everolimus
,21107682,progression-free survival,"ORR was 19.1%, with a disease control rate of 83.0% and median progression-free survival of 30.7 weeks.",Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107682/),weeks,30.7,252471,DB01590,Everolimus
,27299325,apparent volume of distribution,"The apparent volume of distribution of the central and peripheral compartment were estimated to be 207 L with a relative standard error (RSE) of 5.0 % and 485 L (RSE 4.2 %), respectively, with an inter-compartmental clearance of 72.1 L/h (RSE 3.2 %).",A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),l,207,252744,DB01590,Everolimus
,27299325,apparent volume of distribution,"The apparent volume of distribution of the central and peripheral compartment were estimated to be 207 L with a relative standard error (RSE) of 5.0 % and 485 L (RSE 4.2 %), respectively, with an inter-compartmental clearance of 72.1 L/h (RSE 3.2 %).",A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),l,485,252745,DB01590,Everolimus
,27299325,inter-compartmental clearance,"The apparent volume of distribution of the central and peripheral compartment were estimated to be 207 L with a relative standard error (RSE) of 5.0 % and 485 L (RSE 4.2 %), respectively, with an inter-compartmental clearance of 72.1 L/h (RSE 3.2 %).",A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),[l] / [h],72.1,252746,DB01590,Everolimus
,27299325,apparent intrinsic clearance,The apparent intrinsic clearance was 198 L/h (RSE 4.3 %).,A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),[l] / [h],198,252747,DB01590,Everolimus
,24935294,C0,"In this phase 3, multicenter, randomized, open-label study, patients were randomized (1:1) to 1 of the 2 groups: everolimus 1.5 mg (targeted C0 of 3-8 ng/mL) plus reduced-dose cyclosporine or mycophenolate mofetil 2 g/d plus standard-dose cyclosporine.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3-8,259795,DB01590,Everolimus
,24935294,trough concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],4.307,259796,DB01590,Everolimus
,24935294,peak concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],13.539,259797,DB01590,Everolimus
,24935294,area under the concentration-time curve,"The average concentration was 7.558 ± 1.4723 ng/mL, area under the concentration-time curve was 90.70 ± 17.667 ng·h/mL, and peak-trough fluctuation was 122.6%.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[h·ng] / [ml],90.70,259798,DB01590,Everolimus
,24935294,trough levels,"The mean everolimus trough levels were within the target ranges at all time points ranging from 3.4 to 5.5 ng/mL (everolimus 0.75 mg twice a day, safety population).",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3.4 to 5.5,259799,DB01590,Everolimus
,34224367,tumor tissue drug concentration,"Median tumor tissue drug concentration determined by mass spectrometry was 24.3 pg/mg (range, 9.2-169.2).",Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34224367/),[pg] / [mg],24.3,260403,DB01590,Everolimus
,21168621,C(0),We enrolled 10 de novo kidney transplant recipients to receive CsA (target C(0) 250-350 ng/mL) and prednisolone as initial therapy.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],250-350,260925,DB01590,Everolimus
,21168621,target,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260926,DB01590,Everolimus
,21168621,trough level,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260927,DB01590,Everolimus
,21168621,trough level,CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],50-100,260928,DB01590,Everolimus
<,21168621,C(max),CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],600,260929,DB01590,Everolimus
,21168621,initial trough everolimus,The mean initial trough everolimus was 5.2 ± 1.5 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],5.2,260930,DB01590,Everolimus
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],15,265254,DB01590,Everolimus
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],59,265255,DB01590,Everolimus
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],90,265256,DB01590,Everolimus
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],1324,265257,DB01590,Everolimus
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,30,265258,DB01590,Everolimus
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,56,265259,DB01590,Everolimus
,23134470,MTDs,Daily and weekly MTDs were 7.5 mg and 70 mg respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),mg,7.5,273848,DB01590,Everolimus
,23134470,MTDs,Daily and weekly MTDs were 7.5 mg and 70 mg respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),mg,70,273849,DB01590,Everolimus
,23134470,Disease control rates,Disease control rates in the daily and weekly cohorts were 71.4% and 44.4% respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),%,71.4,273850,DB01590,Everolimus
,23134470,Disease control rates,Disease control rates in the daily and weekly cohorts were 71.4% and 44.4% respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),%,44.4,273851,DB01590,Everolimus
<,29574974,trough levels,"In transplant patients, the approved dose of 0.75-1 mg twice daily (BID) results in subtherapeutic trough levels (<6 μg l-1 ) and that a higher starting dose of 2.25-3 mg BID is required.",A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29574974/),[μg] / [l],6,274094,DB01590,Everolimus
